These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15718163)

  • 21. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating molecular design resources within modern drug discovery research: the Roche experience.
    Stahl M; Guba W; Kansy M
    Drug Discov Today; 2006 Apr; 11(7-8):326-33. PubMed ID: 16580974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.
    Hardy LW; Peet NP
    Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial drug discovery: is small pharma the solution?
    Boggs AF; Miller GH
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective.
    Rodrigues AD
    Pharm Res; 1997 Nov; 14(11):1504-10. PubMed ID: 9434267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug discovery and natural products: end of an era or an endless frontier?
    Li JW; Vederas JC
    Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The agony and ecstasy of "OMIC" technologies in drug development.
    Bilello JA
    Curr Mol Med; 2005 Feb; 5(1):39-52. PubMed ID: 15720269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Discovery Technology Europe 2005 - IBC's Ninth Annual Conference and Exhibition.
    Austin S
    IDrugs; 2005 May; 8(5):370-3. PubMed ID: 15883912
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there a best strategy for drug discovery?
    Warne P; Page C
    Drug News Perspect; 2003 Apr; 16(3):177-82. PubMed ID: 12819816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Delivery 2007--New technologies, partnering and strategies for the future.
    Stevenson L
    IDrugs; 2007 Jun; 10(6):388-90. PubMed ID: 17642001
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioinformatics in the pharmaceutical industry.
    Lyall A
    Trends Biotechnol; 1996 Aug; 14(8):308-12. PubMed ID: 8987464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iconix Biosciences, Inc.
    Fielden MR; Halbert DN
    Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift.
    Sams-Dodd F
    Drug Discov Today; 2013 Mar; 18(5-6):211-7. PubMed ID: 23131208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.
    Razvi ES
    IDrugs; 2005 Oct; 8(10):796-8. PubMed ID: 16254794
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry.
    Zambrowicz BP; Turner CA; Sands AT
    Curr Opin Pharmacol; 2003 Oct; 3(5):563-70. PubMed ID: 14559104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iconix Pharmaceuticals, Inc.--removing barriers to efficient drug discovery through chemogenomics.
    Engelberg A
    Pharmacogenomics; 2004 Sep; 5(6):741-4. PubMed ID: 15335294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of novel biomedicine based on genome science.
    Baba Y
    Eur J Pharm Sci; 2001 Apr; 13(1):3-4. PubMed ID: 11292562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tackling the chemogenomic space by novel screening technologies.
    Mayr LM
    Ernst Schering Res Found Workshop; 2006; (58):111-73. PubMed ID: 16709002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.